PMV Pharmaceuticals, Inc. — Q1 2022 Form 10-Q
Business context and period: Unaudited results for the three months ended March 31, 2022, compared with Q1 2021; balance-sheet comparisons are with December 31, 2021. PMV is a clinical-stage precision oncology company developing small-molecule therapies targeting mutant p53. It has no approved products and has generated no revenue.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 or prior balance-sheet date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $11.8 million | $7.5 million |
| General and administrative expense | $6.8 million | $4.2 million |
| Total operating expenses | $18.6 million | $11.7 million |
| Net loss | $18.4 million | $11.6 million |
| Net loss per share, basic and diluted | $0.41 | $0.26 |
| Cash used in operating activities | $18.0 million | $12.9 million |
| Cash, cash equivalents and marketable securities | $294.8 million | $314.1 million at Dec. 31, 2021 |
| Working capital | $276.4 million | $289.1 million at Dec. 31, 2021 |
There is no product revenue or gross margin to report. Interest income, net was $0.2 million. Cash, cash equivalents and marketable securities declined $19.3 million from year-end; cash and cash equivalents alone were $115.8 million. The company reported $23.2 million in total liabilities, including $11.7 million in operating lease liabilities; it reported no financial debt. Accumulated deficit was $186.2 million.
Material changes and operating developments
- Operating expenses increased $6.9 million year over year. R&D rose $4.3 million, mainly from $3.7 million of increased development spending as PC14586 advanced in its Phase 1/2 trial, plus higher personnel and stock-based compensation.
- G&A increased $2.6 million, primarily from higher personnel and office costs, finance and legal support, and Princeton facility costs.
- Investing activities used $38.8 million, chiefly reflecting purchases of marketable securities, partly offset by maturities; financing provided $0.1 million from stock-option exercises.
- PMV signed a lease for a 50,581-square-foot Princeton office and laboratory facility extending through 2032. Total future minimum lease payments were reported as $16.7 million net of reimbursements, with $11.7 million present value of lease liabilities.
Outlook, risks and other notable items
- Management expects substantial additional losses and increased R&D investment. It stated that available cash, cash equivalents and marketable securities were expected to fund operations at least through 2023; the filing also states management believes resources are adequate for at least the next 12 months. These estimates depend on assumptions and spending could exceed expectations.
- PC14586 is in a Phase 1/2 clinical trial, and received FDA Fast Track Designation in October 2020 for locally advanced or metastatic solid tumors with a p53 Y220C mutation. Clinical success, regulatory approval and future revenue are uncertain.
- Risks include clinical and regulatory failure, need for additional financing, competition, reliance on third-party research and manufacturing providers, and potential disruption from COVID-19 and geopolitical events, including the Russia-Ukraine conflict and related sanctions.
- The company reported no material legal proceedings, no material changes to most previously disclosed risk factors other than the added international-operations risks, and effective disclosure controls as of March 31, 2022.
Important facts for investors to verify
- Clinical-trial progress and safety/efficacy data for PC14586, including enrollment and development timelines.
- Cash burn, investment spending and whether the stated runway through 2023 remains supported by updated operating plans.
- Potential need for financing: the company has an effective shelf registration for up to $150 million but had not sold shares under it as of the filing.
- Princeton facility costs and reimbursements, and the effect of lease commitments on future cash requirements.
- Exposure of marketable securities to valuation changes: Q1 included a $0.6 million unrealized loss on securities.